Fusion Antibodies plc
Company Profile
Fusion Antibodies plc (AIM: FAB) is a contract research organisation providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.
Investor Access
Management will announce its unaudited interim results for the six months ended 30 September 2022 on Monday 5th December 2022.
Management will hold a presentation for Investors through the digital platform, Investor Meet Company, on Friday 9th December 2022 at 10:00 relating to its interim results for the six months ended 30 September 2022. Investors can sign up to Investor Meet Company for free, by clicking: https://www.investormeetcompany.com/fusion-antibodies-plc/register-investor
Monday 5th December 2022
Event | Date |
Year End | 31 March |
Half Year End | 30 September |
Preliminary Results* | August |
Interim Results* | November |
AGM* | September |
* Months based on previous announcements of this kind